Ultromics

What is Ultromics?

Ultromics is a healthcare technology company whose EchoGo AI detects heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis from echocardiograms. It analyzes standard echo studies after acquisition.

Key capabilities of Ultromics

• EchoGo Heart Failure: FDA 510(k) cleared diagnostic aid for HFpEF
• EchoGo Amyloidosis: FDA 510(k) cleared screening tool for cardiac amyloidosis
• Single-view input: Needs one four-chamber apical view
• Workflow return: Results return to ultrasound and PACS systems
• Reimbursement path: CPT code 0932T assigned to EchoGo Heart Failure
• Breakthrough designation: Both products hold FDA Breakthrough Device Designation

How Ultromics works

The AI analyzes routine echocardiograms once acquired and returns results into existing clinical systems. It is cloud-based and needs a single four-chamber apical view. A clinician reviews the output, since both are cleared as aids rather than autonomous diagnosis.

Who uses Ultromics?

Cardiology and echo labs. The vendor lists deployments at Mayo Clinic, City of Hope and University Hospitals. EchoGo Heart Failure reports 90.3% sensitivity and 86.1% specificity, and Amyloidosis 84.5% and 89.7%.

Ultromics pricing

Ultromics does not publish pricing. EchoGo Heart Failure has a CPT billing pathway under code 0932T.

Ultromics alternatives

Alternatives include Anumana for ECG-based cardiac AI, Eko Health for AI stethoscopes, and Us2.ai for automated echo measurements.